Terms: = Breast cancer AND EML4, ENSG00000143924, 27436 AND Treatment
12 results:
1. Malignant Pleural Effusion and Its Current Management: A Review.
Skok K; Hladnik G; Grm A; Crnjac A
Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31443309
[TBL] [Abstract] [Full Text] [Related]
2. Recurrent eml4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Church AJ; Calicchio ML; Nardi V; Skalova A; Pinto A; Dillon DA; Gomez-Fernandez CR; Manoj N; Haimes JD; Stahl JA; Dela Cruz FS; Tannenbaum-Dvir S; Glade-Bender JL; Kung AL; DuBois SG; Kozakewich HP; Janeway KA; Perez-Atayde AR; Harris MH
Mod Pathol; 2018 Mar; 31(3):463-473. PubMed ID: 29099503
[TBL] [Abstract] [Full Text] [Related]
3. Mutations of the EGFR, K-ras, eml4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract] [Full Text] [Related]
4. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
5. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract] [Full Text] [Related]
6. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.
Khoo BL; Warkiani ME; Tan DS; Bhagat AA; Irwin D; Lau DP; Lim AS; Lim KH; Krisna SS; Lim WT; Yap YS; Lee SC; Soo RA; Han J; Lim CT
PLoS One; 2014; 9(7):e99409. PubMed ID: 24999991
[TBL] [Abstract] [Full Text] [Related]
7. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.
Chung C; Christianson M
J Oncol Pharm Pract; 2014 Feb; 20(1):11-28. PubMed ID: 23493335
[TBL] [Abstract] [Full Text] [Related]
8. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract] [Full Text] [Related]
9. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract] [Full Text] [Related]
10. [Will targeted therapies replace chemotherapy?].
Collignon J; Jerusalem G
Rev Med Liege; 2012; 67 Spec No():29-36. PubMed ID: 22690483
[TBL] [Abstract] [Full Text] [Related]
11. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract] [Full Text] [Related]
12. Recent developments and future perspectives of personalized oncology.
Grüllich C; von Kalle C
Onkologie; 2012; 35 Suppl 1():4-7. PubMed ID: 22286581
[TBL] [Abstract] [Full Text] [Related]
